— Side effects, contraindications, interactions

The whole safety picture, fourteen rows.

Compiled from peer-reviewed literature, our advisor panel's clinical judgment, and field reports from patients. We mark frequency as commonly observed (≥1 in 10), occasional (1–10%), or rare (<1%). Severity is editorial — a 'critical' tag means stop and call a clinician.

Tolerable Notable Serious Critical / stop
— 01

Tirzepatide

GLP-1/GIP dual agonist GI common
SIDE EFFECTS
  • Nausea, diarrhea, constipationHighest in first 4 weeks of titration.
    Common
  • Injection-site reactionMild redness at SQ site. Rotate sites weekly.
    Common
  • FatigueOften resolves within 2–3 weeks of dose stability.
    Occasional
  • PancreatitisSame risk profile as semaglutide.
    Rare
  • Acute kidney injuryVolume depletion from severe nausea/vomiting → AKI.
    Rare
CONTRAINDICATIONS
  • MEN2 or MTC historyBoxed warning.
  • Pancreatitis historyDocumented prior episode → contraindicated.
  • Severe hepatic impairmentLimited data; consult prescriber.
DRUG & SUBSTANCE INTERACTIONS
  • Insulin/sulfonylureasPre-emptive dose reduction.
  • Oral contraceptivesUse barrier method for 4 wk after each dose escalation.
  • WarfarinMonitor INR more frequently.
— 02

Semaglutide

GLP-1 agonist GI common
SIDE EFFECTS
  • NauseaMost common in titration phase.
    Common
  • Decreased appetiteExpected.
    Common
  • Diabetic retinopathy progressionIn pre-existing retinopathy with rapid HbA1c drop. Baseline eye exam recommended.
    Occasional
  • PancreatitisDiscontinue if confirmed.
    Rare
CONTRAINDICATIONS
  • MEN2 or MTC historyBoxed warning.
  • Severe gastroparesisWill worsen significantly.
DRUG & SUBSTANCE INTERACTIONS
  • Insulin/sulfonylureasHypoglycemia risk.
  • LevothyroxineDelayed absorption — re-check TSH 6–8 weeks after start.
— 03

NAD+

COENZYME MILD PROFILE
SIDE EFFECTS
  • Please configureAdd specific medical side effects via the Shopify editor to replace this placeholder.
    N/A
CONTRAINDICATIONS
— Universal contraindications

These apply to every compound on this site.

Pregnancy & lactation

No medication on this site has adequate human safety data in pregnancy or breastfeeding. Categorical contraindication, no exceptions.

Active malignancy

Growth-factor and GH-axis activity is not appropriate in active cancer or recent (5-year) history of MEN2/MTC. See per-compound notes for exceptions.

Under 18

Insufficient pediatric safety data across the full panel. We do not ship to or accept research-use attestations from minors.

Active infection

Pause regenerative treatments during acute bacterial or viral infection. GLP-1 family is acceptable but watch for additive nausea.

Concurrent polypharmacy

Insulin, sulfonylureas, GH replacement, blood thinners, immunosuppressants — review the per-compound interaction list and consult a prescriber.